secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0001493152-23-041652
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa Pharmaceuticals presents at Orphan Drugs Congress; no material new data disclosed
--------------------------------------------------------------------------------

- Dr. David Young, President of R&D, presented on Nov 16, 2023 at 2:40 PM ET at the 20th Orphan Drugs and Rare Diseases Global Congress in Boston.
- Presentation title: 'Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial'.
- Presentation furnished as Exhibit 99.1 but exhibit text not provided; no specific numbers, milestones, or guidance detailed in the 8-K.
- Company undertakes no obligation to update this Reg FD disclosure; no changes to business or financial condition reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315223041652/0001493152-23-041652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315223041652/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer